Elimination of Gd-DTPA by means of hemodialysis.
After intravenous administration of Gd-DTPA (0.1 mmol/kg) hemodialysis was performed five times within 6 days in a patient with endstage renal failure. During the fifth hemodialysis a blood sample of 5 ml was withdrawn and Gd-concentration was measured in plasma at 342.247 nm using the method of Inductively Coupled Plasma Atomic Emission Spectrometry. Gd-concentration measured in venous and arterial blood was 6 x 10(-6) mol/liter, corresponding to 1.5% of the dose administered. If these data can be confirmed in more patients with endstage renal failure, this is the proof of effective hemodialysis of Gd-DTPA in a clinical setting.
Haustein
J
J
Department of Clinical Research Diagnostics, Schering AG Berlin, F.R.G.
Schuhmann-Giampieri
G
G
D000328:Adult; D002528:Cerebellar Neoplasms / Q000175:diagnosis; D003287:Contrast Media; D019786:Gadolinium DTPA; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000493:pharmacokinetics*; D006435:Renal Dialysis
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA